← Back to Clinical Trials
Recruiting NCT06074549

NCT06074549 DynamX Bioadaptor Global Post-Market Registry: Clinical Trial of the Elixir Medical DynamX Coronary Bioadaptor System

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06074549
Status Recruiting
Phase
Sponsor Elixir Medical Corporation
Condition Coronary Artery Disease
Study Type OBSERVATIONAL
Enrollment 5,000 participants
Start Date 2024-03-10
Primary Completion 2028-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
DynamX Novolimus-eluting Coronary Bioadaptor System

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 5,000 participants in total. It began in 2024-03-10 with a primary completion date of 2028-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this registry is to confirm the safety, and performance of the DynamX Coronary Bioadaptor System in patients with coronary artery disease.

Eligibility Criteria

Inclusion Criteria: 1. Over 18 years of age 2. Patient understands the trial requirements and treatment procedures and provides informed consent 3. Patient indicated for PCI with stent implantation and receive at least one DynamX Bioadaptor implant in accordance with the product's Instructions for Use (IFU). Exclusion Criteria: 1. Target Lesion(s) in the left main artery 2. Prior venous or arterial bypass grafts 3. In-stent restenosis 4. Patient is currently participating in another clinical trial with an investigational device or an investigational drug that has the potential to impact study results (e.g., anti-thrombotic or anti-platelet medications) that has not yet completed its primary endpoint 5. Patient is, in the opinion of the Investigator, unable to comply with the requirements of the study protocol or is unsuitable for the registry for any reason

Contact & Investigator

Central Contact

Lisa Tanner

✉ ltanner@ElixirMedical.com

📞 +1 408 636 2000

Frequently Asked Questions

Who can join the NCT06074549 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Coronary Artery Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06074549 currently recruiting?

Yes, NCT06074549 is actively recruiting participants. Contact the research team at ltanner@ElixirMedical.com for enrollment information.

Where is the NCT06074549 trial being conducted?

This trial is being conducted at Pölten, Austria, Willemstad, Curacao, Jakarta, Indonesia, Jakarta, Indonesia and 11 additional locations.

Who is sponsoring the NCT06074549 clinical trial?

NCT06074549 is sponsored by Elixir Medical Corporation. The trial plans to enroll 5,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology